Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT01711528
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 3
- Registration Number
- NCT01706666
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Baylor Medical Center, Garland, Texas, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
- First Posted Date
- 2012-10-01
- Last Posted Date
- 2017-10-27
- Target Recruit Count
- 21
- Registration Number
- NCT01696474
- Locations
- 🇮🇹
Cattedra di Ematologia CTMO Università degli Studi di Parma, Parma, Italy
🇮🇹Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
🇮🇹Ospedale San Bortolo, Vicenza, Italy
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01695941
- Locations
- 🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
🇺🇸Montefiore Medical Center-Einstein Campus, Bronx, New York, United States
🇺🇸Montefiore Medical Center - Moses Campus, Bronx, New York, United States
Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- University of Florida
- Registration Number
- NCT01680796
Bortezomib in Patients With Chronic Graft Versus Host Disease
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Mehrdad Abedi, MD
- Target Recruit Count
- 16
- Registration Number
- NCT01672229
- Locations
- 🇺🇸
University of California Comprehensive Cancer Center, Sacramento, California, United States
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 142
- Registration Number
- NCT01668719
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸The Mark H Zangmeister Center, Columbus, Ohio, United States
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT01653418
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
- Conditions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT01647165
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- University Hospital of Crete
- Target Recruit Count
- 53
- Registration Number
- NCT01633645
- Locations
- 🇬🇷
Air Forces Military Hospital of Athens Athens, Greece, Athens, Greece
🇬🇷METAXA Hospital, B' Pathology Department, Athens, Greece
🇬🇷SOTIRIA Hospital, Medical Oncology Department, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.